Cancer Immunotherapy Fallout From Roche’s Bladder Cancer Failure – TheStreet.com
TheStreet.com |
Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure
TheStreet.com The announcement from Roche (RHHBY) Wednesday that Tecentriq failed to prolong survival in bladder cancer is a surprising setback for the Swiss drug maker with implications and new questions for the entire cancer immunotherapy field. Will the FDA … Roche's Tecentriq fails trial, raising questions about approval |
